Lung cancer
Stories
-
Tiragolumab and atezolizumab: median progression-free survival 7.00 vs 5.55 months
In participants with high PD-L1 expression, median progression-free survival was 7.00 months with tiragolumab plus atezolizumab and 5.55 months with placebo plus atezolizumab. The record now holds randomized Phase III results for 620 participants with untreated non-small cell lung cancer.